Connect Biopharma Holdings Ltd current report, Q4 FY2023

Full document

Connect Biopharma Holdings Limited — Form 6-K Summary

Reporting period: Form 6-K furnished for November 2023; dated November 21, 2023. Connect Biopharma is a foreign private issuer that files annual reports on Form 20-F.

Business Context and Key Developments

  • Connect Biopharma announced an exclusive license and collaboration agreement covering rademikibart in Greater China.
  • The Board appointed current director Kan Chen, Ph.D. to the Compensation Committee, filling a vacancy created by Derek DiRocco, Ph.D.’s previously announced resignation from the Board.
  • The Company reported positive topline Stage 2 maintenance results from its China pivotal trial of rademikibart in patients with moderate-to-severe atopic dermatitis.

Financial and Operating Metrics

  • The filing does not provide revenue, profit or loss, operating cash flow, cash balance, liquidity, debt, or margin information.
  • Under the Greater China agreement, the Licensor is entitled to receive a RMB150 million, or approximately US$21 million, upfront payment.
  • The Licensor may receive up to RMB875 million, or approximately US$120 million, in development and commercial milestones, plus royalties of up to low-double-digit percentages of net sales.
  • U.S. dollar translations use an exchange rate of RMB7.3166 per US$1.00 as of October 31, 2023.

Material Changes and Clinical Results

Greater China License Agreement

  • Connect Biopharma HongKong Limited and Suzhou Connect Biopharma Co., Ltd. granted Simcere Pharmaceutical Co., Ltd. exclusive rights to develop, manufacture and commercialize rademikibart for all indications in mainland China, Hong Kong, Macau and Taiwan.
  • Connect Biopharma retains rights in all other markets.
  • The Licensor will complete ongoing China clinical trials and related analyses in atopic dermatitis. The parties stated that a China new drug application submission for atopic dermatitis was on track for the end of the first quarter of 2024.
  • Simcere will be responsible for the China atopic dermatitis application and the costs of future clinical studies for additional indications in Greater China.

Stage 2 Maintenance Trial

  • Patients achieving EASI-50 during the 16-week Stage 1 were randomized to rademikibart 300 mg every two weeks, or Q2W, with 113 patients, or every four weeks, or Q4W, with 112 patients. Stage 1 nonresponders received open-label Q2W treatment, with 86 patients.
  • Among patients who achieved IGA 0/1 or EASI-75 at Week 16, Week 52 maintenance rates were:
    • IGA 0/1: 87.2% for Q4W and 76.0% for Q2W.
    • EASI-75: 91.9% for Q4W and 91.7% for Q2W.
  • Among patients achieving EASI-50 at Week 16, IGA 0/1 at Week 52 was 62.6% for Q4W versus 41.8% at Week 16, and 59.1% for Q2W versus 30.9% at Week 16.
  • In the same population, EASI-75 at Week 52 was 84.6% for Q4W versus 73.6% at Week 16, and 84.8% for Q2W versus 68.5% at Week 16.
  • Among patients achieving a clinically meaningful reduction in peak pruritus, 95.2% maintained the reduction with Q4W dosing and 81.6% with Q2W dosing at Week 52.
  • Among patients achieving a clinically important reduction in dermatology quality-of-life score, 90.0% maintained the reduction with Q4W dosing and 93.4% with Q2W dosing.
  • Both dosing regimens were generally well tolerated, with no new safety signals reported. One discontinuation due to an adverse event, pregnancy, occurred in the open-label Q2W arm.

Guidance, Outlook, Risks and Unusual Items

  • The stated outlook is submission of a China atopic dermatitis new drug application by the end of the first quarter of 2024; submission, acceptance, approval and timing remain uncertain.
  • The Company cautioned that the clinical, regulatory, commercial and partnership expectations described in the filing are forward-looking and may not be achieved.
  • Key risks include failure to meet development or commercial milestones, regulatory delays or non-approval, differing clinical outcomes, inability to commercialize rademikibart, and the possibility that the Greater China partnership will not meet expectations.
  • The filing incorporates the reported information by reference into specified Form F-3 and Form S-8 registration statements.
  • Portions of the license agreement exhibit were omitted because the Company determined they were not material and disclosure could cause competitive harm.

Important Facts for Investors to Verify

  • Whether the RMB150 million upfront payment was received and how it is recognized under the Company’s accounting policies.
  • The specific development and commercial milestones, royalty terms and other provisions in the complete license agreement.
  • Whether the China atopic dermatitis new drug application was submitted by the stated target date and its subsequent regulatory status.
  • Detailed clinical-trial design, statistical analyses, patient populations, confidence intervals and complete safety data underlying the topline results.
  • Cash resources, operating burn rate, financing needs, revenue recognition and potential milestone or royalty receipts in subsequent periodic filings.
  • Whether the reported maintenance results are confirmed in later regulatory submissions or peer-reviewed disclosures.